Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications

References

• Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev. 2002; 16:9–12.
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005; 54:107–116.
   PubMed Web of Science ®Google Scholar
• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:995–1008.
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9:1123–1124.
   PubMed Web of Science ®Google Scholar
• Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001; 98:952–957.
   PubMed Web of Science ®Google Scholar
• Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, Amadori S. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110:2924–2930.
   PubMed Web of Science ®Google Scholar
• Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007; 92:1695–1698.
   PubMed Web of Science ®Google Scholar
• Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998; 188:1185–1190.
   PubMed Web of Science ®Google Scholar
• Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001; 2:945–951.
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, J Tschopp. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B-cell growth. J Exp Med. 1999; 189:1747–1756.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: A tutorial on B-cell survival. Annu Rev Immunol. 2003; 21:231–264.
   PubMed Web of Science ®Google Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002; 3:822–829.
   PubMed Web of Science ®Google Scholar
• Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood. 2003; 101:4464–4471.
   PubMed Web of Science ®Google Scholar
• Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, McCabe S, Qiu WR, Kornuc M, Xia XZ, Guo J, Stolina M, Boyle WJ, Sarosi I, Hsu H, Senaldi G, Theill LE. APRIL and TALL-I and receptors BCMA and TACI: System for regulating humoral immunity. Nat Immunol. 2000; 1:252–256.
   PubMed Web of Science ®Google Scholar
• Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005; 12:637–648.
   PubMed Web of Science ®Google Scholar
• Kimberley FC, van Bostelen L, Cameron K, Hardenberg G, Marquart JA, Hahne M, Medema JP. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J. 2009; 23:1584–1595.
   PubMed Web of Science ®Google Scholar
• Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, Harada M, Horiuchi T. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 64:1065–1067.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmstrom V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006; 8:R167.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol. 2007; 65:92–98.
   PubMed Web of Science ®Google Scholar
• Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol. 2005; 25:189–201.
   PubMed Web of Science ®Google Scholar
• Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A, Diamond B, Madaio MP, Davidson A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol. 2004; 173:3524–3534.
   PubMed Web of Science ®Google Scholar
• Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T-cell activation and collagen-induced arthritis in mice. Nat Immunol. 2001; 2:632–637.
   PubMed Web of Science ®Google Scholar
• Sutherland AP, Mackay F, Mackay CR. Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther. 2006; 112:774–786.
   PubMed Web of Science ®Google Scholar
• Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, Dorner T, Salama A. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007; 136:309–314.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen Z, Li H, Chen X, Xu J, Gu D, Du W, Zheng C, Zhang L, Huang Y, Ren Q, Yang R. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity. 2009; 42:112–119.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 2009; 113:2386–2393.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, Tada Y, Maruyama N, Okochi H, Tamaki K. Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid. J Dermatol Sci. 2007; 46:53–60.
   PubMed Web of Science ®Google Scholar
• Thangarajh M, Masterman T, Rot U, Duvefelt K, Brynedal B, Karrenbauer VD, Hillert J. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol. 2005; 167:210–214.
   PubMed Web of Science ®Google Scholar
• Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001; 97:198–204.
   PubMed Web of Science ®Google Scholar
• Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, Maniatis A, Mouzaki A. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004; 103:2645–2647.
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996; 87:4245–4254.
   PubMed Web of Science ®Google Scholar
• Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol. 2007; 124:182–189.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004; 63:1096–1103.
   PubMed Web of Science ®Google Scholar
• O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004; 199:91–98.
   PubMed Web of Science ®Google Scholar
• Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008; 111:2755–2764.
   PubMed Web of Science ®Google Scholar
• Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, Brink R, Mackay F, Hodgkin PD, Tangye SG. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003; 112:286–297.
   PubMed Web of Science ®Google Scholar
• Yang M, Hase H, Legarda-Addison D, Varughese L, Seed B, Ting AT. B-cell maturation antigen, the receptor for a proliferation-inducing ligand and B-cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol. 2005; 175:2814–2824.
   PubMed Web of Science ®Google Scholar
• Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: Toward a molecular understanding of B-cell homeostasis. Cell Biochem Biophys. 2009; 53:1–16.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev.. 2008; 19:263–276.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Motomura S, Podack ER. APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol. 2008; 38:3450–3458.
   PubMed Web of Science ®Google Scholar
• Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002; 169:4314–4321.
   PubMed Web of Science ®Google Scholar